<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Improving the Prognostic Ability through Better Use of Standard Clinical Data -The Nottingham Prognostic Index as an Example</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-03-03">March 3, 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Klaus-Jürgen</forename><surname>Winzer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Klinik für Gynäkologie mit Brustzentrum</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anika</forename><surname>Buchholz</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Institut für Medizinische Biometrie und Statistik</orgName>
								<orgName type="department" key="dep2">Department für Medizinische Biometrie und Medizinische Informatik</orgName>
								<orgName type="institution">Universitätsklinikum Freiburg</orgName>
								<address>
									<settlement>Freiburg, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Institut für Medizinische Biometrie und Epidemiologie</orgName>
								<orgName type="institution">Universitätsklinikum Hamburg-Eppendorf</orgName>
								<address>
									<settlement>Hamburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Schumacher</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Institut für Medizinische Biometrie und Statistik</orgName>
								<orgName type="department" key="dep2">Department für Medizinische Biometrie und Medizinische Informatik</orgName>
								<orgName type="institution">Universitätsklinikum Freiburg</orgName>
								<address>
									<settlement>Freiburg, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Willi</forename><surname>Sauerbrei</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Institut für Medizinische Biometrie und Statistik</orgName>
								<orgName type="department" key="dep2">Department für Medizinische Biometrie und Medizinische Informatik</orgName>
								<orgName type="institution">Universitätsklinikum Freiburg</orgName>
								<address>
									<settlement>Freiburg, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Improving the Prognostic Ability through Better Use of Standard Clinical Data -The Nottingham Prognostic Index as an Example</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-03-03">March 3, 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">4A074D31500A63F942439F01F224ABE9</idno>
					<idno type="DOI">10.1371/journal.pone.0149977</idno>
					<note type="submission">Received: September 16, 2015 Accepted: February 8, 2016 Data Availability Statement: Data are available as supporting information. Funding: The authors have no support or funding to report.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:24+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p><s>Prognostic factors and prognostic models play a key role in medical research and patient management.</s><s>The Nottingham Prognostic Index (NPI) is a well-established prognostic classification scheme for patients with breast cancer.</s><s>In a very simple way, it combines the information from tumor size, lymph node stage and tumor grade.</s><s>For the resulting index cutpoints are proposed to classify it into three to six groups with different prognosis.</s><s>As not all prognostic information from the three and other standard factors is used, we will consider improvement of the prognostic ability using suitable analysis approaches.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods and Findings</head><p><s>Reanalyzing overall survival data of 1560 patients from a clinical database by using multivariable fractional polynomials and further modern statistical methods we illustrate suitable multivariable modelling and methods to derive and assess the prognostic ability of an index.</s><s>Using a REMARK type profile we summarize relevant steps of the analysis.</s><s>Adding the information from hormonal receptor status and using the full information from the three NPI components, specifically concerning the number of positive lymph nodes, an extended NPI with improved prognostic ability is derived.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>The prognostic ability of even one of the best established prognostic index in medicine can be improved by using suitable statistical methodology to extract the full information from standard clinical data.</s><s>This extended version of the NPI can serve as a benchmark to assess the added value of new information, ranging from a new single clinical marker to a derived index from omics data.</s><s>An established benchmark would also help to harmonize the statistical analyses of such studies and protect against the propagation of many false</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Understanding and improving the prognosis of patients with a disease or health condition is a priority in clinical research and practice.</s><s>In the PROGnosis RESearch Strategy (PROGRESS) series a framework to improve research of interrelated prognosis themes has been proposed <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref>.</s><s>Two of the key topics are the role of prognostic factors and prognostic models.</s><s>Since the beginning of the century, much of the research has been focused on issues related to personalized or stratified medicine with the assessment of genetic markers and analyses of high dimensional data as the challenge for researchers in many disciplines.</s><s>A substantial part of such studies investigates issues for patients with cancer, breast cancer thereby being the disease considered most often <ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref>.</s><s>Unfortunately, most of the results from the very large number of individual studies have not been validated and the number of clinically useful markers is pitifully small <ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref>.</s><s>There are many potential pitfalls inherent in the complex process of successfully developing and validating a marker from omics data <ref type="bibr" target="#b14">[15]</ref>.</s></p><p><s>For some years it has been discussed to improve prediction rules through the integration of clinical and gene expression data <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref>.</s><s>However, applying combined prediction rules at a broader level would cause difficulties in many (smaller) centers and increase costs.</s><s>Obviously, to be cost effective the predictive value of a combined prediction rule would need to be much larger than the predictive value of rules based on some generally available clinical measurements.</s><s>In other terms, the added value of the genetic information would need to be 'substantial'.</s><s>Yet, assessing the added predictive value of genetic data to clinical data is far from trivial.</s><s>Boulesteix and Sauerbrei <ref type="bibr" target="#b20">[21]</ref> critically discuss various approaches for the construction of combined prediction rules and review procedures that assess and validate the added predictive value.</s><s>Obviously, adding predictive value from genetic information to a 'good' clinical model is much more difficult than adding value to a 'less good' clinical model.</s><s>Knowing about difficulties in using a combined model in practice, it follows that one may try to 'optimize' the predictive value from a model based on clinical data.</s><s>The use of a combined predictor would only be sensible if the genetic information adds substantial predictive value to such an 'optimized' clinical predictor.</s></p><p><s>Notation in this area of research is confusing.</s><s>Despite of using terms like 'prediction' and 'added predictive value' we will not consider the role of 'predictive factors', a term popular in cancer research where it usually implies that a factor is relevant for treatment decision.</s><s>Such aspects require additional investigations (for example analysis of subgroups or investigation for an interaction between treatment and a factor) which will not be considered here <ref type="bibr" target="#b3">[4]</ref>.</s><s>This paper concentrates on prognostic factors and prognostic models <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3]</ref>.</s><s>The latter is a formal combination of multiple prognostic factors and the term predictor is popular and will be used here.</s></p><p><s>A number of prognostic models are published for many diseases, but for practical use the situation is often confusing.</s><s>For example, there are over 100 models for prostate cancer <ref type="bibr" target="#b21">[22]</ref> and for chronic kidney disease Collins et al <ref type="bibr" target="#b22">[23]</ref> identified 14 prediction models featuring 43 different risk predictors.</s><s>However, in breast cancer the situation seems to be better than for most other areas.</s><s>Similar to the other cases, many classification schemes have been proposed, most of which did not survive validation <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b25">25]</ref>.</s><s>But more than 30 years ago, the Nottingham Prognostic Index (NPI) was proposed, has been sufficiently validated, is well accepted and also used in clinical practice <ref type="bibr" target="#b26">[26]</ref>.</s><s>The three components lymph node stage, grade and tumor size are combined to a continuous index.</s><s>Originally two and later up to five cutpoints were proposed to create three to six categories with different prognosis <ref type="bibr" target="#b26">[26,</ref><ref type="bibr" target="#b27">27]</ref>.</s><s>The simplicity of the NPI is certainly an important criterion for its clinical relevance, but it also implies that some prognostic information may not be used to improve the NPI.</s><s>Applying elaborated statistical methods-we explain the key ideas and cite relevant references but do not provide all detailsto a clinical registry data set <ref type="bibr" target="#b28">[28]</ref> we extract the full information of the data and derive a modified version of the NPI with improved prognostic ability.</s><s>We will illustrate that the continuous variables tumor size and number of positive nodes exhibit more information and will investigate whether another six standard variables carry prognostic information in addition to the NPI.</s><s>With overall survival as the outcome of interest we will use the Cox model <ref type="bibr" target="#b29">[29]</ref> for analysis.</s><s>An often neglected but relevant issue is the verification of the model assumptions.</s><s>We will check whether important assumptions of the Cox proportional hazard model are acceptable or whether modifications are required.</s><s>A fundamental assumption is the proportionality of the hazard functions <ref type="bibr" target="#b30">[30]</ref>.</s><s>As known for many other diseases, prognostic effects varying in time have also been shown for clinical <ref type="bibr" target="#b31">[31,</ref><ref type="bibr" target="#b32">32]</ref> and for genetic data <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b33">33]</ref> in breast cancer research.</s><s>Nevertheless, even in top-ranking cancer journals it is rather an exception to report the check of this important assumption <ref type="bibr" target="#b34">[34,</ref><ref type="bibr" target="#b35">35]</ref> and we speculate that suitable checks have often not been conducted.</s><s>There is a severe danger of misspecification and models derived may be (partly) wrong with a potential consequence of incorrect medical decisions.</s><s>However, poor reporting prevents to assess whether a relevant check of the model was not done or just not reported.</s><s>To improve on this aspect several reporting guidelines, of which TRIPOD <ref type="bibr" target="#b36">[36]</ref> and REMARK <ref type="bibr" target="#b37">[37]</ref> are most relevant for the type of study discussed here, have been developed.</s><s>They aim to Enhancing the QUAlity and Transparency Of health Research (EQUATOR network).</s></p><p><s>As discussed in the PROGRESS series <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref> it is important having a suitable prognostic index with good discriminative ability for many diseases.</s><s>Larger data bases with standard clinical information are often available and prognostic indices exhibiting the full information from the data could be derived in a similar manner as done here.</s><s>Using the NPI as an example we illustrate how to derive an index for a survival time outcome and how to assess its prognostic ability.</s><s>In order to increase readability and understandability of the various analyses we will provide a technical summary of the study similar to the REMARK profile <ref type="bibr" target="#b38">[38]</ref>.</s></p><p><s>A 'good' predictor summarizing the standard information from clinical data can be used as a suitable benchmark to assess the added value of new information.</s><s>In the context of research such a benchmark would be highly relevant for the discussion about clinical predictors, molecular predictors or combined predictors.</s><s>Compared to a 'good' clinical predictor as an adequate benchmark it is more difficult for a molecular predictor or a combined predictor to substantially increase the discriminative ability.</s><s>This will influence the role of predictors in patient management.</s><s>In section 2 we introduce the data, section 3 introduces the statistical methods used to derive multivariable prognostic models and to assess the prognostic ability of a model.</s><s>In section 4 we present results and propose an extended version of the NPI.</s><s>Although it needs only information about hormone receptor status in addition to the three original NPI components, it has much larger discriminative ability than the NPI.</s><s>With the main emphasize on the importance of a 'standard' prognostic index, methodological issues to derive such an index and its clinical relevance, we discuss our findings in section 5.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods and Data</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data</head><p><s>All patients had primary surgery for breast cancer between January 1984 and December 1998 at the surgical clinic of the Charité hospital in Berlin and were followed up until 2007.</s><s>Nearly all of them were operated by the first author and he had them included in a clinical database, consisting of 2062 cases.</s><s>In order to define a more homogeneous and sensible patient population for analysis, we had defined several inclusion and exclusion criteria.</s><s>Accordingly, we excluded 502 patients, leaving 1560 patients for the analysis.</s><s>Main reasons for exclusion were breast cancer in situ (n = 134) and age older than 80 years (n = 123), further reasons are briefly summarized in the REMARK type profile (Table <ref type="table" target="#tab_0">1</ref>) and details can be found in Winzer et al <ref type="bibr" target="#b28">[28]</ref>.</s><s>We use data from clinical follow-up and consider overall survival (OS) with all causes of death as an event.</s><s>The number of events for OS is 221.</s><s>During 1984 and 1998 treatment of patients changed severely worldwide.</s><s>Winzer et al <ref type="bibr" target="#b28">[28]</ref> provide details about treatment strategies in three periods <ref type="bibr">(1984-1990, 1991-1993, 1994-1998)</ref>.</s><s>During the first period, most of the patients (73.4%) had a mastectomy (±) radiotherapy and did not receive adjuvant treatments.</s><s>In the third period 61% had breast conserving treatment (±) radiotherapy and a systemic treatment.</s><s>For details of local and adjuvant therapy, measurement techniques of prognostic factors, influence of prognostic factors on choice of treatment and further details concerning followup, we refer to Winzer et al <ref type="bibr" target="#b28">[28]</ref> and cited references.</s><s>To account for different treatment strategies, all Cox models were stratified according to therapy strata.</s></p><p><s>The study was retrospective and we did not obtain informed consent from the patients.</s><s>However, only anonymized data is used.</s><s>There was no necessity to contact an Ethical Committee for this re-analysis of data.</s><s>The patient records were not de-identified before entry in the original database.</s><s>However, before starting the first analysis <ref type="bibr" target="#b28">[28]</ref> KJW had received a positive vote by the authorized local data protection person for an analysis of the data base from breast cancer patients of the Charité Hospital.</s><s>In addition this positive vote allows comparing followup data with the information given in the cancer registry and data from the residence registration office in Berlin.</s><s>It is signed by Heiko Wiese and dated May 16 2012.</s><s>KJW sent the database to AB to subtract the relevant information.</s><s>AB created a subfile which was used in the earlier paper <ref type="bibr" target="#b28">[28]</ref> and in this new analysis.</s><s>Information specifically referring to the patient (such as name and address) was not stored.</s><s>Specific dates (such as birthday or date of surgery) were only used to create relevant information such as age, survival time or year of surgery but will not be included in the publicly available file.</s><s>This file will only include all variables mentioned in Table <ref type="table" target="#tab_0">1</ref> for the 1560 patient included in the analysis.</s><s>To destroy the chronological order of patients' entry in the database AB randomized the order of patients' records in the publicly available file.</s><s>With these procedures we protect against identification of individual patients while allowing conducting analyses presented.</s><s>KJW and AB have separate lists allowing them to restore patient identification.</s></p><p><s>The distribution of the nine standard prognostic factors and of treatment is given in S1 Table <ref type="table">.</ref></s><s>Tumor grade has a larger percentage of missing data (13.9%) and some of the other factors have missing data in a smaller percentage of patients.</s><s>In order to use all patients for the multivariable analysis we imputed missing data in two steps.</s><s>In a first step, missing information was replaced based on clinical criteria (related clinical factors), if applicable.</s><s>Since this strategy was not very successful, it was decided to drop all observations with more than three missing values in the standard prognostic factors (N = 2) and impute the remaining missing values using single univariable imputation sampling <ref type="bibr" target="#b39">[39]</ref> based on observed survival times.</s><s>In all analyses we will use the data after imputation for missing information (N = 1560).</s><s>The distribution of the resulting NPI is given in S1 Fig.</s><s><ref type="figure">As</ref> nodes and grade both contribute with 1 to 3 points to the Nottingham Prognostic Index, the resulting distribution of the NPI has several peaks.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nottingham Prognostic Index</head><p><s>The three components lymph node stage (LN), grade and tumor size are combined to the index</s></p><formula xml:id="formula_0">NPI ¼ LNð1 À 3Þ þ Grade ð1 À 3Þ þ maximum diameter ðcmÞ 0:2;</formula><p><s>where LN is a categorized version of the number of positive lymph nodes (1 -zero positive nodes, 2 -one to three positive nodes, 3 -four or more positive nodes).</s><s>In our data, this gives an observed range of NPI from 2.02 (LN negative, grade 1, 0.1 cm) to 8.2 (LN Stage 3, grade 3, size 11.0cm)</s><s>Originally the two cutpoints 3.4 and 5.4 and later up to five cutpoints (2.4,</s><s>3.4, 4.4, 5.4 and 6.4) were proposed to create three to six categories with different prognosis <ref type="bibr" target="#b26">[26,</ref><ref type="bibr" target="#b27">27]</ref>.</s></p><p><s>Here, we will use the notation NPIcont to refer to the continuous values of NPI, NPI(3) and NPI( <ref type="formula">6</ref>) for classification schemes with three or six prognostic groups.</s><s>For the three NPI(3) groups we will use the abbreviations NPI(3)-1, NPI(3)-2 and NPI(3)-3, with NPI(3)-1 denoting the group with the best prognosis.</s><s>The six prognostic groups from NPI(6) will be denoted as in Blamey et al <ref type="bibr" target="#b27">[27]</ref>: Excellent Prognostic Group (EPG) with an observed NPI range of 2.08-2.4,</s><s>Good (GPG) 2.42 to 3.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The Cox Model</head><p><s>The Cox proportional hazard model was used to estimate the effect of variables and to derive multivariable models <ref type="bibr" target="#b29">[29]</ref>.</s><s>As any regression model, the Cox model makes several important assumptions, including proportional hazards and linear relationships between continuous covariates and the log hazard function.</s><s>It is well-known that assumptions are often violated and the importance to check for them is stressed in the REMARK guidelines <ref type="bibr" target="#b38">[38]</ref> and in many other papers and books.</s><s>For studies with long-term follow-up the proportional hazard (PH) assumption is often critical, for example when a portion of patients can be considered cured after having survived for a longer period.</s><s>To check the PH assumption for a categorical variable plots of log(-log survival time) versus log time may be used.</s><s>They should be approximately parallel <ref type="bibr" target="#b40">[40]</ref>.</s><s>Other approaches investigate whether a Cox model with an extension for time-varying effects fit the data significantly better.</s><s>Such approaches investigate for a potential interaction of a covariate with time.</s><s>We will use the fractional polynomial time (FPT) algorithm <ref type="bibr" target="#b41">[41]</ref> which was developed to detect and model potential time-varying effects with a significance level of 1%.</s><s>The decision to use FPT is based on personal preferences and results of a comparison of several approaches <ref type="bibr" target="#b42">[42]</ref>.</s></p><p><s>We will use the class of fractional polynomials (FPs) to investigate whether the popular assumption of a linear effect is acceptable or whether a non-linear function improves the data fit severely and is therefore an important argument against the linearity assumption <ref type="bibr" target="#b43">[43]</ref>.</s><s>For categorical variables with an ordinal scale (such as tumor grade) we will use ordinal dummy coding and allow collapsing two neighboring categories in the model building process.</s><s>For details see chapter 3.3 in <ref type="bibr" target="#b43">[43]</ref> Royston and Sauerbrei.</s></p><p><s>For our registry data it is not possible to get unbiased estimates of effects for different treatments.</s><s>However, as stressed in the REMARK guidelines (Item 10 f and Item 17) <ref type="bibr" target="#b38">[38]</ref>, it is important that different treatments are accounted for in the analysis.</s><s>Details about treatment modalities and arguments to consider, type of surgery (mastectomy or breast conserving therapy) and the application of radiotherapy (yes, no) and systemic therapy (yes, no) as the three most relevant aspects of treatment given, are discussed in Winzer et al <ref type="bibr" target="#b28">[28]</ref>.</s><s>To account for therapy we stratified all analyses with the Cox regression model for the eight strata defined by the combination of the three binary variables.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Multivariable Fractional Polynomials to Model Continuous Variables</head><p><s>A method for variable selection is required when a larger number of variables need to be assessed for their influence on an outcome of interest.</s><s>For each continuous variable it is also necessary to estimate their influence by considering a (non-linear) functional form.</s><s>Assuming a linear function or categorizing the continuous variable and using step-functions are the preferred approaches in medicine.</s><s>However, severe weaknesses of both approaches have been known for a long time.</s><s>For details see Box 4 of the REMARK guidelines <ref type="bibr" target="#b38">[38]</ref>.</s><s>To avoid the severest weaknesses, the class of fractional polynomials and the corresponding function selection procedure (FSP) have been proposed <ref type="bibr" target="#b43">[43,</ref><ref type="bibr" target="#b44">44]</ref>.</s><s>To derive a multivariable regression model, the multivariable fractional polynomial (MFP) procedure, which combines the fractional polynomial FSP with the backward elimination procedure for variable selection, has gained popularity in the health sciences.</s><s>Deriving a multivariable prognostic model for patients with breast cancer, details of the procedure are given <ref type="bibr" target="#b45">[45]</ref>, key parts of the philosophy to prefer MFP to other multivariable approaches are discussed and illustrated <ref type="bibr" target="#b43">[43,</ref><ref type="bibr" target="#b46">46]</ref>.</s></p><p><s>In order to select a MFP model, the significance level is the key parameter to determine the number of variables included and the complexity of functional forms for continuous variables.</s><s>For both parts we will use the popular 5% level, denoted as MFP(0.05,</s><s>0.05).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discriminative Ability of a Model</head><p><s>Kaplan-Meier plots are a popular and simple way to assess the discriminative ability of a classification scheme.</s><s>However, such plots do not give an overall measure and it is difficult to compare several classification schemes.</s><s>If a continuous score is categorized by using various cutpoints it is easily possible to present plots which can be very misleading.</s><s>Differences of estimated survival rates depend heavily on the chosen cutpoint(s) and by creating smaller subgroups at both ends of a prognostic score, Kaplan-Meier plots may indicate extreme differences between subgroups.</s><s>Specifically if the numbers of patients at risk are not given, such plots bear the risk of severe misinterpretation.</s><s>The REMARK guidelines <ref type="bibr" target="#b38">[38]</ref> (see item 15) explicitly state that numbers at risk should be provided for selected time points.</s><s>We will present Kaplan-Meier plots for NPI(3) and NPI <ref type="bibr" target="#b5">(6)</ref>.</s></p><p><s>Based on the idea of measuring the separation between several Kaplan-Meier curves and simultaneously taking into account the relative frequencies of each category, the D-statistic was proposed <ref type="bibr" target="#b47">[47]</ref>.</s><s>It assumes that the proportional hazards assumption is not seriously violated, otherwise the use of this measure is doubtable.</s><s>The D statistic can be transferred to a R 2 -type measure of explained variation.</s><s>D and R 2 D have been chosen because the latter 'appear to be the best overall' in a large simulation study comparing 17 R 2 -type measures proposed for survival models <ref type="bibr" target="#b48">[48]</ref>.</s><s>In addition we will use the c-index.</s><s>It was chosen because it has been well known for a long time and it seems to be the measure used most often.</s><s>However, for survival data it has some weaknesses and it is preferable to use a modified version <ref type="bibr" target="#b49">[49]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Software</head><p><s>Analyses were conducted with Stata/SE 13.1 <ref type="bibr" target="#b50">[50]</ref> and some user-written Stata programs were used for imputation of missing values <ref type="bibr" target="#b39">[39]</ref>, calculation of explained variation <ref type="bibr" target="#b51">[51]</ref> and Cox models with time-varying effects (stmfpt, available at https://portal.uni-freiburg.de/imbi/</s><s>Royston-Sauerbrei-book).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>To provide an overview of analyses conducted and reasons for them, we summarize this information in the bottom part of the REMARK type profile (Table <ref type="table" target="#tab_0">1</ref>).Information about the initial data analysis (IDA 1) is provided in chapter 2. As a result we have 1560 patients of which 221 died during the follow-up period.</s><s>All analyses are based on this population.</s><s>First we will only consider NPI (A1-A3) before trying to improve this index by using the full information from the three NPI components number of nodes, tumor size and tumor grade (A4-A5).</s><s>Finally we investigate improvement of the prognostic ability by considering the added value of other standard variables and by using all available information to derive a MFP model (A6-A8).</s><s>To compare the discriminative ability of NPI and various variants considered we summarize results from several measures of discrimination.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Correlation between Factors of Interest</head><p><s>The correlation structure between potential prognostic variables can have a severe influence on the result of multivariable model building procedures.</s><s>It is most easily summarized by giving absolute values of pairwise Spearman rank correlation coefficients.</s><s>Very large correlations (! 0.7) are observed between NPI and no. of pos.</s><s>lymph nodes (0.71), NPI and tumor grade (0.70), as well as age and menopausal status (0.73).</s><s>In addition, larger (0.5-0.7) and medium sized (0.3-0.5) correlations are present for NPI and tumor size (0.59) and tumor size and no. of pos.</s><s>lymph nodes (0.31), respectively.</s><s>The absolute value of all other correlation coefficients is below 0.3 and we consider such values as having only a negligible influence on the result of multivariable model building.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discriminative Ability of the NPI Categories</head><p><s>In Fig 1 <ref type="figure">we</ref> show the survival estimates for three and six groups, respectively, derived by categorizing the NPI.</s><s>With a minor exception for a short term period (up to about 2 years) even the six groups are well separated over the period of 15 years.</s><s>Estimates of five-year survival rates are 95%, 89% and 65% for the three groups from NPI(3) (Table <ref type="table" target="#tab_2">2</ref>).</s><s>NPI(6) splits each of the three groups into two separate groups and the resulting estimates (Fig 1 <ref type="figure" target="#fig_2">and S2 Table)</ref> indicate much better separation.</s><s>The two most extreme groups from NPI(6) have estimated five year survival rates of 97% (EPG) and 48% (VPG), respectively.</s><s>However, only a small percentage of the study population belongs to the two extreme groups (10.8%toEPG and 6.3% to VPG).</s></p><p><s>In Table <ref type="table" target="#tab_3">3</ref> we give estimates of the hazard ratios from Cox models.</s><s>For NPI(3) the estimate of HR for the group with the worst prognosis (NPI &gt; 5.4) compared to the group with the best prognosis (NPI &lt;3.4) is 4.80.</s><s>The estimated HR for the two extreme groups from NPI(6) is 14.91.</s><s>These extreme categories compare the small groups with NPI &lt; = 2.4 with NPI &gt; 6.4.</s><s>When interpreting other HR estimates given in Table <ref type="table" target="#tab_3">3</ref>, please note that the reference categories differ between NPI (3) and NPI(6) analyses.</s><s>These results illustrate that it is often simple to derive extremely well separated subgroups and to receive large values for the estimate of the hazard ratio.</s><s>Obviously, corresponding subgroups are small, confidence intervals are large and the clinical relevance of such small subgroups with an extremely good or poor prognosis is limited.</s><s>This is also reflected by the small differences of the measures of separation (e.g. the Cindex increases from 0.65 (NPI(3)) to 0.67 (NPI(6)) and R 2 D as an overall measure derived from D increase from 0.217 to 0.245; right part of Table <ref type="table" target="#tab_3">3</ref>.).Hence the impression of a much better separation of NPI(6) compared to NPI(3) based on the Kaplan-Meier plots is misleading.</s><s>In addition, it has to be noted that overfitting of the data is likely and results in overestimation of the difference between the two most extreme subgroups, specifically for the NPI(6) classification.</s><s><ref type="formula">6</ref>)) indicate some minor violations of the PH assumption at the beginning of the follow-up time.</s><s>Checking for non-proportionality by using the fractional polynomial time (FPT) algorithm did not exhibit a significant time-varying effect.</s><s>P values of the test for non-proportionality (FP2 function vs. PH) were 0.0647 for NPI (3) and 0.343 for NPI <ref type="bibr" target="#b5">(6)</ref>, respectively.</s><s>Altogether we conclude that the PH assumption is acceptable.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Extensions of NPI Categories by Using Full Information</head><p><s>Continuous NPI.</s><s>To avoid problems caused by categorization it may be more suitable to provide estimates for the continuous variable NPI.</s><s>The estimated increase in risk for one unit (e.g. from 3.13 to 4.13 or from 5.09 to 6.09) is 1.67 (see last line of Table <ref type="table" target="#tab_3">3</ref>).</s><s>Using NPI as a continuous variable hardly influences the measures for discrimination.</s></p><p><s>Estimating the effect for the continuous variable NPI we have assumed that a linear function describes the influence of NPI on our outcome.</s><s>Using the MFP function selection procedure and a 5% significance level we have checked that non-linear functions do not improve the fit and that the linearity assumption is acceptable.</s><s>The test of the proportional hazards assumption did not exhibit any significant violations.</s><s>MFP of the three components.</s><s>The NPI consists of the three components: tumor size, no of positive lymph nodes and tumor grade.</s><s>In the original analysis node involvement was categorized and three groups were considered.</s><s>The relative weight of each component was estimated as given in the Introduction.</s><s>Here, we consider a possible improvement of the prognostic ability by (i) using the full information on the number of positive nodes, (ii) allowing non-linear functions to estimate the effect of the two continuous variable and (iii) re-estimating the relative weights of each of the three variables.</s><s>In Table <ref type="table" target="#tab_4">4</ref> we give estimates of the three components in univariable Cox models assuming a linear effect for tumor size and the number of positive nodes.</s><s>Results of the FP analyses show that non-linear functions describe the functional relationship with the outcome better (in terms of the deviance).</s><s>The Multivariable FP (MFP) approach selects a model with a linear effect for tumor size, a non-linear effect  for the number of nodes and combines categories 1 and 2 for grade, estimating an increased risk for grade 3 compared to the others.</s><s>For univariable analyses Fig <ref type="figure" target="#fig_3">3</ref> illustrates the difference between the popular approach to assume a linear functional relationship for a continuous variable and the fractional polynomial approach which checks whether a non-linear function from the FP class fits the data significantly better.</s><s>Differences indicate that models assuming a linear functional relationship underestimate the risk for very low values such as 2 positive nodes or a tumor size of 5 mm and overestimate the risk (severely) for very large values such as 30 positive nodes or a tumor size of 100 mm.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Univariable Assessment of the Added Value of Other Standard Factors</head><p><s>In addition to the three NPI components there are six additional standard factors available.</s><s>In Table <ref type="table" target="#tab_5">5</ref> we give estimates of their effects in a univariable model.</s><s>Age, menopausal status and histology have no influence on survival time, whereas the effects of the three binary variables hormone receptor status, vessel invasion and lymphatic vessel invasion are significant at the 5% level.</s><s>The effect of hormone receptor status is strongest and it is the only effect remaining significant after adjustment for NPIcont.</s><s>These results indicate that hormone receptor status is the only of the six variables which has a significant effect in addition to NPI.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Multivariable Models</head><p><s>The multivariable model given in Table <ref type="table" target="#tab_5">5</ref> includes NPI and the six additional factors, assuming linear effects for continuous variables.</s><s>For an MFP analysis it is the 'starting' model and the algorithm investigates simultaneously whether any of the variables can be eliminated and whether any of the continuous variables have a non-linear effect.</s><s>This 'full' model includes several variables with a 'weak' or no effect and only NPIcont and hormone receptor status are significant.</s><s>Using MFP(0.05,</s><s>0.05) to select a simpler model, only NPIcont and hormone receptor status remain in the model.For NPI a linear function is chosen and the estimated effect is 1.60 (1.43-1.80)</s><s>per unit increase for NPI.</s><s>This simple model estimates that hormone receptor positive tumors have a severely decreased risk of 0.49 (0.37-0.64) compared to receptor negative tumors.</s><s>In Fig 4 <ref type="figure">we</ref> give Kaplan-Meier estimates of survival rates for the six groups derived by a combination of NPI(3) and receptor status (see also S3 Table <ref type="table">)</ref>.</s><s>This figure illustrates that receptor status has a strong influence on the survival rate for patients in the worst NPI group (10 year survival rates for receptor positive are 0.69 whereas the corresponding value for receptor negative patients is 0.44).</s><s>Over the full observation period survival rates of receptor positive patients from NPI(3)-3 are very similar to survival rates of receptor negative patients from NPI (3)-2.</s><s>For patients from the NPI(3)-2 group hormone receptor status has also a strong influence on the survival rate (10 year rate is 0.86 for pos and 0.65 for neg), whereas the hormone receptor effect is small for NPI(3)-1 patients.</s><s>Estimates at 10 years are 0.92 (pos), 0.89 (neg).</s><s>For the NPI(3)-1 group the effect of hormone receptor status seems to vary slightly in time.</s></p><p><s>To use all information from the nine available variables we repeat the MFP analysis from above, but consider the three NPI components separately.</s><s>This analysis would also allow eliminating one or more of the NPI components if they have no significant effect in a multivariable context.</s><s>However, all three components remain and hormone receptor is added in the final model.</s><s>We propose to use the term extended Nottingham Prognostic Index for this resulting model and define NPIext ¼ 0:108 Ã tumor size ðcmÞ þ 0:543 Ã logðno: pos: nodes þ 1Þ þ 0:404 Ã Ind ðif tumor grade is 2 or 3Þ À 0:766 Ã Ind ðif hormone receptor is positiveÞ;</s></p><p><s>where Ind is the indicator function taking the values 0 (condition is not fulfilled) or 1 (condition is fulfilled).</s><s>Compared to NPI it adds hormone receptor status as a binary variable, estimates a non-linear functional influence of the number of positive lymph nodes and weighs the relative influence of the variables differently (Table <ref type="table" target="#tab_6">6</ref>).</s><s>The results broadly coincide with the MFP model for the three NPI components (see Table <ref type="table" target="#tab_4">4</ref>), but the inclusion of hormone receptor status has slightly changed the functional form for the number of nodes.</s><s>Please note that the chosen power terms are different (-0.5 in Table <ref type="table" target="#tab_4">4</ref> and 0 (log function) in Table <ref type="table" target="#tab_6">6</ref>), implying that parameter estimates are very different, but the corresponding functions are very similar (not presented).</s><s>The addition of hormone receptor status seems to have the most important influence on the effect of tumor grading.</s><s>In the model in Table <ref type="table" target="#tab_4">4</ref> grade 1 and 2 were collapsed (meaning that the prognosis of these two categories is identical and only grade 3 has a worse prognosis) whereas grade 2 was collapsed with 3 in the new model (grade 1 has a better prognosis than the others; see Table <ref type="table" target="#tab_6">6</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Comparison of Models</head><p><s>To compare performance of various models we give estimates of the C-index, the D-measure and corresponding R 2 D for the major' models considered in the paper.</s><s>Compared to NPI(3) our final MFP model improves the C-index from 0.651 to 0.714.</s><s>This notable improvement is a result of several minor improvements starting with the use of the full NPI information instead of categorization with three categories, some improvement by using the full information from the number of positive nodes and the strongest increase comes from adding hormone receptor status.</s><s>A similar improvement is indicated by the D-measure and R 2 D .</s><s>An improved R 2 value from 0.217 to 0.290 is substantial (34%), but may to some extent be caused by overfitting the data.</s><s>The potential problem of overfitting does not apply to the three models solely depending  on the NPI.</s><s>By using resampling methods it would be possible to (partly) correct for overoptimism, but that is beyond the scope of this paper.</s><s>Further investigations in a related methodological paper will allow deriving estimates for the performance measures which are less prone to overoptimism.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In a paper written in a time before the era of genetic information had really started, Sauerbrei et al <ref type="bibr" target="#b45">[45]</ref> stressed the importance of an accepted prognostic model based on standard factors: 'An important step for an improvement in summarizing information from prognostic factors would be a widely accepted standard prognostic model.</s><s>We see the Nottingham Prognostic Index as the most often validated and accepted classification scheme.</s><s>As recently published for nodenegative patients where, in addition to changes to the weights of the component of the NPI, in one of our proposals only age was added to the NPI <ref type="bibr" target="#b23">[24]</ref>, we see the results from the NPI and our proposals as a starting point for an urgently needed accepted and sensible description of the influence of standard factors.'</s><s>At that time in breast cancer the prognostic effect of more than 100 factors was discussed controversially and the idea was to have a standard model and to check whether a new factor improved the separation of prognostic groups derived from a prognostic model.</s><s>At least, a standard model would have helped to standardize analyses across studies and to avoid many claims concerning the relevance of a new prognostic factor.</s><s>Nowadays, there is still a controversial discussion concerning factors such as Her2-neu and Ki-67 <ref type="bibr" target="#b52">[52]</ref> and since the intensive research on molecular data, the necessity for a 'good' predictive model based on 'standard' factors has even increased, at least when clinical usefulness is considered an important criterion.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Use and Usefulness of the NPI</head><p><s>The NPI was developed more than 30 years ago using standard information and (from today's point of view) a simple approach to derive a Cox model.</s><s>It is very well validated in many studies worldwide and oftentimes used in patient care.</s><s>Beside of some disagreement with point 4, we fully agree with the synopsis concerning the usefulness of prognostic indices from a group of authors from Nottingham, some of which belong to the original developers of the NPI <ref type="bibr" target="#b27">[27]</ref>.</s></p><p><s>Blamey et al state 'The NPI has satisfied the criteria which should be applied to all claimed methods for prognostic prediction, namely ability 1.</s><s>To separate patients into groups with significantly differing survival chances.</s></p><p><s>2. To achieve wide separation, i.e. to recognise a 'cured' group and a group with poor survival.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>3.</head><p><s>To place a sufficient percentage of cases into each group.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>4.</head><p><s>To be applicable to all operable breast cancers, i.e. small, screen detected as well as symptomatic and those in patients of young age.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>5.</head><p><s>To have been prospectively validated intra-centre in a new tumour set from that on which it was derived and intercentre and internationally.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>6.</head><p><s>To be capable of measurement in all units and inexpensive.'</s></p><p><s>Because NPI satisfies the most important criteria for a sensible and useful prognostic index, we consider it as a suitable starting point when trying to derive an improved classification scheme.</s><s>Improvement has to be judged by the added value related to a suitable measure of prognostic separation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Potential Improvements of the NPI</head><p><s>Deriving a very simple index with few points and using a simple classification scheme was important for practical use in the last century.</s><s>Measures indicate improved separation by extending the original proposal with three categories (NPI(3)) to six categories (NPI( <ref type="formula">6</ref>)).</s><s>However, the weights of the three components tumor size, number of positive nodes and tumor grade remained unchanged, categorization disregards parts of the relevant information from continuous data and finally no further factor was added to the NPI in later research.</s></p><p><s>As in many studies before, the prognostic groups from NPI(3) and NPI(6) separate our patient population well.</s><s>However, it is well known that the number of positive lymph nodes is a prognostic factor with a very strong effect and the NPI uses only a simple classification into three groups, therefore ignoring a lot of the information from this marker.</s><s>For example, the NPI uses the same weight for patients with four and with 25 positive lymph nodes.</s><s>It is becoming more and more accepted that categorization has severe weaknesses when developing a multivariable model and that continuous variables should be modelled in a suitable way <ref type="bibr" target="#b45">[45]</ref>.</s><s>Categorization is required for medical decision making but it has severe weakness when deriving multivariable models.</s><s>Categorization should be postponed to the final step of developing a prognostic classification scheme.</s></p><p><s>By using the full information from the continuous variables tumor size and number of positive lymph nodes and by adding hormone receptor status, we could improve the prognostic ability.</s><s>Compared to many other studies investigating the value of new factors added to the NPI, our 'added value' from the better use of standard factors is much larger.</s><s>By using three suitable measures of separation we summarize the information from all 'major' models in Table <ref type="table" target="#tab_1">7</ref>.</s><s>It is well known that scores derived in a data dependent way may be too optimistic and need validation in independent data <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b36">36,</ref><ref type="bibr" target="#b38">38]</ref>.</s><s>As all components from our new score are generally available, validation studies can be easily conducted.</s></p><p><s>While we concentrated on a more suitable modelling of the data, using a two-step approach to try to improve the prognostic ability of a score is also possible.</s><s>Rakha et al <ref type="bibr" target="#b53">[53]</ref> started by using multivariable clustering techniques to identify seven key molecular classes.</s><s>Within each class they estimate the effect of several clinicopathological factors in a multivariable Cox model.</s><s>Simply by chance the size of the estimate effects varies and a specific factor (say tumor size) gets a large effect in some of the molecular classes and a small effect in others.</s><s>For each molecular class this gives a separate (NPI-type) formula and this complex classification scheme is called Nottingham Prognostic Index Plus (NPI+).</s><s>In principle, NPI+ is a very complex index proposing interactions between the molecular classes and the clinicopathological factors.</s><s>Unfortunately it is not possible to assess how much NPI+ improves on NPI(3) or NPI(6) as presentation of results is restricted to Kaplan-Meier plots for survival time.</s><s>Measures of the discriminative ability of the indices are not given.</s><s>For many years NPI(3) has been used for decision making in clinical practice.</s><s>Barton et al <ref type="bibr" target="#b52">[52]</ref> investigated for agreement between risk categorizations by NPI(3) and the IHC4+C score (also categorized into 3 groups).</s><s>Risk classifications (low, medium, high) agreed in 60.4%.</s><s>Studies with access to relevant data of the IHC4+C score could check whether our modified NPI index agrees better with the IHC4+C score, specifically differences in the NPI(medium) category are severe.</s><s>However, differences in risk classifications do not directly imply different treatments for patients.</s><s>The comparisons of treatments require randomized trials and the importance of risk classifications for treatment decisions needs investigations in relevant subgroups and corresponding tests for interaction with treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methodological Issues</head><p><s>Compared to the methodology for multivariable model building at the time the NPI was developed, statistical methodology has seen severe improvements.</s><s>Unfortunately, many of these developments are ignored in practice <ref type="bibr" target="#b54">[54]</ref>.</s><s>In addition, reporting of many studies in the health sciences is insufficient and incomplete <ref type="bibr" target="#b36">[36,</ref><ref type="bibr" target="#b38">38]</ref>, making the assessment of results difficult.</s><s>By providing a REMARK type profile <ref type="bibr" target="#b38">[38]</ref> we give details about our patient population, illustrate all steps of our model development and assessment and refer to some highly relevant checks of important assumptions of the Cox model.</s><s>Unfortunately, there are no generally accepted stateof-the-art analyses and measures <ref type="bibr" target="#b54">[54]</ref>.</s><s>For many years some of us have worked in this area and we used our preferred approaches.</s><s>We are well aware that the results are too optimistic if model development and model assessment are based on the same data.</s><s>Therefore we expect that the added value of our new proposal is slightly overestimated.</s><s>This and several other relevant methodological issues will be discussed in a follow-up paper.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary</head><p><s>Using improved statistical methodology and generally available standard information we propose to slightly extend the NPI.</s><s>Using the full information from continuous variables we derive the index NPIext ¼ 0:108 Ã tumor size ðcmÞ þ 0:543 Ã logðno: pos: nodes þ 1Þ þ 0:404 Ã Ind ðif tumor grade is 2 or 3Þ À0:766 Ã Ind ðif hormone receptor is positiveÞ which leads to an important increase in its prognostic ability and a related classification scheme can be easily derived and generally used for patient handling.</s><s>Most of the statistical issues illustrated in the context of breast cancer and the Nottingham Prognostic Index apply in a similar manner to other projects aiming to derive a prognostic index for a survival time outcome.</s><s>To better illustrate which analyses and checks of assumptions are relevant we summarize all steps conducted in a REMARK type profile <ref type="bibr">(Altman,</ref><ref type="bibr" target="#b38">[38]</ref>).</s><s>We propose to use such an approach to derive a suitable measure summarizing the information from standard factors in other diseases.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p><s>Using the well-established NPI as an example, we show that it is possible to derive an extended index NPIext with substantially improved prognostic ability.</s><s>Using more sophisticated statistical methodology we propose to weight tumor size, no of positive nodes and tumor grade differently and to add hormone receptor status.</s><s>As all four prognostic markers are available for most breast cancer patients, it can be used for patient management worldwide.</s><s>For prognostic research in breast cancer, it can be used to summarize standard clinical information, also serving as a benchmark to assess the added value of new clinical or molecular markers in single studies as well as in the assessment of a marker or a genomic signature in meta-analysis.</s><s>Statistical methods used are generally available and can be used for similar analyses in other diseases.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>4; Moderate I (MPG I) 3.42 to 4.4, Moderate II (MPG II) 4.42 to 5.4, Poor (PPG) 5.42 to 6.4 and very poor (VPG) 6.42-8.2.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig 1 .</head><label>1</label><figDesc><div><p><s>Fig 1. Kaplan-Meier estimates of survival probabilities for prognostic groups defined by the Nottingham Prognostic Index.</s><s>Top NPI(3)-3 groups, below NPI(6)-6 groups.</s><s>doi:10.1371/journal.pone.0149977.g001</s></p></div></figDesc><graphic coords="9,36.00,78.01,379.17,586.43" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig 2 .</head><label>2</label><figDesc><div><p><s>Fig 2. Log-log plot for NPI(3).</s><s>Log-log plot to check the proportional hazards assumption of the Cox-model for three prognostic groups according to NPI(3).</s><s>doi:10.1371/journal.pone.0149977.g002</s></p></div></figDesc><graphic coords="11,200.01,78.01,211.92,158.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig 3 .</head><label>3</label><figDesc><div><p><s>Fig 3. Functional form for no. of positive nodes for two models.</s><s>Predictor for univariable analysis of no. of positive lymph nodes derived by two Cox models assuming a linear effect (dashed line) or the significant improvement from the class of FP models (solid line).</s><s>doi:10.1371/journal.pone.0149977.g003</s></p></div></figDesc><graphic coords="12,200.01,78.01,211.92,158.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig 4 .</head><label>4</label><figDesc><div><p><s>Fig 4. Kaplan-Meier curve for combinations of NPI(3) and hormone receptor.</s><s>NPI groups are defined as 1: NPI&lt;3.4;</s><s>2: 3.4 NPI 5.4; 3: NPI&gt;5.4.</s><s>doi:10.1371/journal.pone.0149977.g004</s></p></div></figDesc><graphic coords="14,200.01,78.01,211.92,160.27" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>REMARK type profile.</s><s>Continuous and categorical.</s><s>Cutpoints as predefined in the literature.</s><s>For details see Blamey et al [27].</s><s>Primary Breast Cancer Patient source: Database Surgical clinic Charité, Berlin.</s><s>All patients with surgery from 1 st Jan. 1984 to 31 st Dec. 1998.</s><s>Excluded 502 63 metastasis, 73 previous carcinoma other than breast cancer, 86 primary breast cancer prior to the study, 134 breast cancer in situ, 8 pt0, 123 older than 80 years, 20 neo-adjuvant chemotherapy, 71 death within first months of surgery, three or more standard prognostic factors missing.</s><s>For some patients, more than one exclusion criterion applied.</s></p></div></figDesc><table><row><cell>a) Patients, treatments and variables</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Study and marker</cell><cell>Remarks</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">Markerhandled M = NPI Further variables v1 = Tumor Size, v2 = No. of pos. Lymph Nodes, v3 = Tumor Grade, v4 = Age, v5 = Histology,</cell></row><row><cell></cell><cell cols="4">v6 = Hormone Receptor Status, v7 = Menopausal Status, v8 = Vessel Invasion, v9 = Lymphatic</cell></row><row><cell></cell><cell cols="2">Vessel Invasion</cell><cell></cell><cell></cell></row><row><cell>Patients</cell><cell>n</cell><cell>Remarks</cell><cell></cell><cell></cell></row><row><cell cols="4">Assessed for eligibility Disease: Analysis 2062 Patients Events Variables considered</cell><cell>Results/ remarks</cell></row><row><cell>IDA 1 1 : Imputation for missing values</cell><cell>1560</cell><cell>NR 2</cell><cell>v1(94), v2 (68), v3(217), v6</cell><cell>Variables (number of patients) with imputed</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(490), v7(54)</cell><cell>values</cell></row><row><cell>A1 3 : NPI (3)</cell><cell>1560</cell><cell>221</cell><cell>NPI</cell><cell>Prognostic value of NPI in 3 categories</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(Table 2, Fig 1, Table 3)</cell></row><row><cell>A2: NPI (6)</cell><cell>1560</cell><cell>221</cell><cell>NPI</cell><cell>6 categories (Fig 1, Table 3)</cell></row><row><cell>C1 A3: NPIcont.</cell><cell>1560</cell><cell>221</cell><cell>NPI</cell><cell>More information from continuous data?</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(Table 3)</cell></row><row><cell>C2: NPIcont. has a linear effect</cell><cell>1560</cell><cell>221</cell><cell>NPI</cell><cell>FP2 function not significantly better, see 4.3.1</cell></row><row><cell>C3: Check of PH 5 in NPIcont.</cell><cell>1560</cell><cell>221</cell><cell>NPI</cell><cell>Non-significant result of FPT (see last</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>paragraph 4.3.1)</cell></row><row><cell>A4: MFP 6 of the three NPI variables (univ. and</cell><cell>1560</cell><cell>221</cell><cell>v1, v2, v3</cell><cell>Table 4</cell></row><row><cell>multivariable)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>A5: Functional form for nodes</cell><cell>1560</cell><cell>221</cell><cell>v2</cell><cell>Fig 3</cell></row><row><cell>A6: Prognostic value and additional value of further</cell><cell>1560</cell><cell>221</cell><cell>NPI, v4, v5, v6, v7, v8, v9</cell><cell>Table 5, Fig 4</cell></row><row><cell>variables (univ. and multiv.)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>A7: MFP using all available information</cell><cell>1560</cell><cell>221</cell><cell>v1, v2, v3, v4, v5, v6, v7,</cell><cell>Final MFP model in Table 6, see 4.5</cell></row><row><cell></cell><cell></cell><cell></cell><cell>v8, v9</cell><cell></cell></row><row><cell>A8: Measures of separation</cell><cell>1560</cell><cell>221</cell><cell>NPI, v1, v2, v3, v4, v5, v6,</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>v7, v8, v9</cell><cell></cell></row></table><note><p><s>Included 1560 Previously untreated.</s><s>Treatment: Local therapy: BCT or mastectomy with or without radiotherapy, adjuvant therapy: chemo (y/n), hormone (y/n).</s><s>For details see Add file 1 and Table 2 in Winzer et al [28] With outcome events 221 Overall survival: death from any cause b) Statistical analyses.</s><s>All analyses using a Cox model are stratified for strata according to therapy.</s><s>There are 8 strata defined by the combination of surgery, radiotherapy (y/n) and systemic therapy (y/n (no chemotherapy and no hormone therapy)) 4 : Check of PH 5 in NPI (3) and in NPI (6) 1560 221 NPI Fig 2, S2 Fig and non-significant result of FPT (see last paragraph 4.2).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 7</head><label>7</label><figDesc></figDesc><table><row><cell>, see 4.6</cell></row></table><note><p><s>REMARK type profile providing an overview of the patient population, variables in the study and analyses conducted.The Nottingham Prognostic Index (NPI) is the marker of main interest.NPI(3) and NPI(6) denote classifications into 3 and 6 prognostic groups, respectively. 1</s><s>data analysis 2 not relevant3Ai-analysis no.i4Ci-check number i of an assumption5Proportional hazards assumption of the Cox model6Multivariable Fractional Polynomial procedure doi:10.1371/journal.pone.0149977.t001</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Survival rates after 5, 10 and 15 years for the categories from NPI(3).</s></p></div></figDesc><table><row><cell></cell><cell>Time</cell><cell>Survivor Function</cell><cell>Std. Error</cell><cell>95% CI</cell></row><row><cell>NPI &lt; 3.4</cell><cell>5</cell><cell>0.954</cell><cell>0.010</cell><cell>[0.930, 0.969]</cell></row><row><cell></cell><cell>10</cell><cell>0.912</cell><cell>0.015</cell><cell>[0.878, 0.936]</cell></row><row><cell></cell><cell>15</cell><cell>0.876</cell><cell>0.029</cell><cell>[0.807, 0.921]</cell></row><row><cell>3.4 NPI 5.4</cell><cell>5</cell><cell>0.891</cell><cell>0.013</cell><cell>[0.862, 0.914]</cell></row><row><cell></cell><cell>10</cell><cell>0.794</cell><cell>0.023</cell><cell>[0.745, 0.835]</cell></row><row><cell></cell><cell>15</cell><cell>0.753</cell><cell>0.036</cell><cell>[0.673, 0.816]</cell></row><row><cell>NPI &gt; 5.4</cell><cell>5</cell><cell>0.652</cell><cell>0.033</cell><cell>[0.584, 0.711]</cell></row><row><cell></cell><cell>10</cell><cell>0.574</cell><cell>0.038</cell><cell>[0.495, 0.645]</cell></row><row><cell></cell><cell>15</cell><cell>0.542</cell><cell>0.048</cell><cell>[0.444, 0.630]</cell></row><row><cell>doi:10.1371/journal.pone.0149977.t002</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Hazard ratios and discriminative ability of NPI.</s></p></div></figDesc><table><row><cell></cell><cell>Coding</cell><cell>log (HR)</cell><cell>Hazard Ratio</cell><cell>95% Confidence interval of HR</cell><cell>R 2 D</cell><cell>C</cell></row><row><cell>NPI (3 categories)</cell><cell>NPI &lt; 3.4</cell><cell>0</cell><cell>1</cell><cell>-</cell><cell>0.217</cell><cell>0.651</cell></row><row><cell></cell><cell>3.4 NPI 5.4</cell><cell>0.54</cell><cell>1.72</cell><cell>[1.16, 2.55]</cell><cell></cell><cell></cell></row><row><cell></cell><cell>NPI &gt; 5.4</cell><cell>1.57</cell><cell>4.80</cell><cell>[3.15, 7.30]</cell><cell></cell><cell></cell></row><row><cell>NPI (6 categories)</cell><cell>NPI 2.4</cell><cell>0</cell><cell>1</cell><cell>0</cell><cell>0.245</cell><cell>0.673</cell></row><row><cell></cell><cell>2.4 &lt; NPI 3.4</cell><cell>0.72</cell><cell>2.06</cell><cell>[0.90, 4.71]</cell><cell></cell><cell></cell></row><row><cell></cell><cell>3.4 &lt; NPI 4.4</cell><cell>1.00</cell><cell>2.72</cell><cell>[1.20, 6.17]</cell><cell></cell><cell></cell></row><row><cell></cell><cell>4.4 &lt; NPI 5.4</cell><cell>1.24</cell><cell>3.45</cell><cell>[1.51, 7.87]</cell><cell></cell><cell></cell></row><row><cell></cell><cell>5.4 &lt; NPI 6.4</cell><cell>1.84</cell><cell>6.32</cell><cell>[2.75, 14.53]</cell><cell></cell><cell></cell></row><row><cell></cell><cell>NPI &gt; 6.4</cell><cell>2.70</cell><cell>14.91</cell><cell>[6.42, 34.66]</cell><cell></cell><cell></cell></row><row><cell>NPI continuous 1</cell><cell></cell><cell>0.51</cell><cell>1.67</cell><cell>[1.49, 1.86]</cell><cell>0.219</cell><cell>0.675</cell></row></table><note><p><s>For three version of NPI estimated hazard ratios (left) and measures of the discriminative ability (right) of the standard CoxPH model.All analyses stratified by the eight treatment strata (see Table1) 1 increase of the hazard ratio for one unit doi:10.1371/journal.pone.0149977.t003</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>Estimated effects of NPI components.</s></p></div></figDesc><table><row><cell>Univariable</cell></row></table><note><p><s>Univariable and multivariable Cox PH models assuming a linear effect for continuous variables or choosing the functional form by using the function selection procedure of the fractional polynomial approach.The significance level for both variables and functions is 0.05.All analyses stratified by the eight treatment strata (see Table1) doi:10.1371/journal.pone.0149977.t004</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 5 .</head><label>5</label><figDesc><div><p><s>Estimated effects of additional variables.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell cols="2">Univariable model</cell><cell></cell><cell></cell><cell cols="2">Multivariable model</cell></row><row><cell></cell><cell></cell><cell>Unadjusted</cell><cell></cell><cell cols="2">Adjusted for NPI*</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Coding</cell><cell>HR</cell><cell>95% CI</cell><cell>HR</cell><cell>95% CI</cell><cell>HR</cell><cell>95% CI</cell></row><row><cell>NPI</cell><cell>continuous</cell><cell>1.67</cell><cell>[1.49, 1.86]</cell><cell>*</cell><cell>*</cell><cell>1.57</cell><cell>[1.39, 1.77]</cell></row><row><cell>Age</cell><cell>continuous</cell><cell>1.00</cell><cell>[0.99, 1.01]</cell><cell>1.00</cell><cell>[0.99, 1.01]</cell><cell>0.99</cell><cell>[0.98, 1.01]</cell></row><row><cell>Histology</cell><cell>invasive ductal</cell><cell>1</cell><cell>-</cell><cell>1</cell><cell>-</cell><cell>1</cell><cell>-</cell></row><row><cell></cell><cell>invasive lobular</cell><cell>0.88</cell><cell>[0.53, 1.44]</cell><cell>0.91</cell><cell>[0.55, 1.49]</cell><cell>0.91</cell><cell>[0.55, 1.50]</cell></row><row><cell></cell><cell>other</cell><cell>0.64</cell><cell>[0.34, 1.20]</cell><cell>0.74</cell><cell>[0.39, 1.40]</cell><cell>0.66</cell><cell>[0.35, 1.26]</cell></row><row><cell>Hormone receptor status</cell><cell>negative</cell><cell>1</cell><cell>-</cell><cell>1</cell><cell>-</cell><cell>1</cell><cell>-</cell></row><row><cell></cell><cell>positive</cell><cell>0.41</cell><cell>[0.32, 0.54]</cell><cell>0.49</cell><cell>[0.37, 0.64]</cell><cell>0.48</cell><cell>[0.37, 0.63]</cell></row><row><cell>Meno-pausal status</cell><cell>pre-menopausal</cell><cell>1</cell><cell>-</cell><cell>1</cell><cell>-</cell><cell>1</cell><cell>-</cell></row><row><cell></cell><cell>post-menopausal</cell><cell>1.05</cell><cell>[0.78, 1.41]</cell><cell>1.14</cell><cell>[0.85, 1.53]</cell><cell>1.35</cell><cell>[0.89, 2.04]</cell></row><row><cell>Vessel invasion</cell><cell>V 0</cell><cell>1</cell><cell>-</cell><cell>1</cell><cell>-</cell><cell>1</cell><cell>-</cell></row><row><cell></cell><cell>V1</cell><cell>1.79</cell><cell>[1.15, 2.78]</cell><cell>1.22</cell><cell>[0.78, 1.92]</cell><cell>1.10</cell><cell>[0.69, 1.76]</cell></row><row><cell>Lymphatic vessel invasion</cell><cell>L 0</cell><cell>1</cell><cell>-</cell><cell>1</cell><cell>-</cell><cell>1</cell><cell>-</cell></row><row><cell></cell><cell>L1</cell><cell>1.62</cell><cell>[1.22, 2.17]</cell><cell>1.24</cell><cell>[0.93, 1.66]</cell><cell>1.21</cell><cell>[0.89, 1.64]</cell></row></table><note><p><s>Univariable (without and with adjustment) and multivariable ('full') CoxPH models.For continuous variables a linear effect is assumed.All analyses stratified by the eight treatment strata (see Table1) * Estimates for effects of NPI vary slightly (1.60-1.67)</s><s>for the 6 different models.</s><s>doi:10.1371/journal.pone.0149977.t005</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 6 .</head><label>6</label><figDesc><div><p><s>MFP model.modelfor the three individual components of NPI and the six variables v4-v9.Five of these variables are eliminated from the final model.Analysis stratified by the eight treatment strata (see Table1) doi:10.1371/journal.pone.0149977.t006</s></p></div></figDesc><table><row><cell></cell><cell>Coding</cell><cell>log (HR)</cell><cell>Hazard Ratio</cell><cell>95% Confidence interval of HR</cell></row><row><cell>Tumor size</cell><cell>in cm (linear)</cell><cell>0.11</cell><cell>1.11</cell><cell>[1.04, 1.19]</cell></row><row><cell>No. of pos. lymph nodes</cell><cell>log(nodes+1)</cell><cell>0.54</cell><cell>1.72</cell><cell>[1.48, 1.99]</cell></row><row><cell>Tumor grade</cell><cell>1</cell><cell>0</cell><cell>1</cell><cell>-</cell></row><row><cell></cell><cell>2 and 3</cell><cell>0.40</cell><cell>1.50</cell><cell>[0.99, 2.26]</cell></row><row><cell>Hormone receptor</cell><cell>negative</cell><cell>0</cell><cell>1</cell><cell>-</cell></row><row><cell></cell><cell>positive</cell><cell>-0.77</cell><cell>0.46</cell><cell>[0.35, 0.61]</cell></row><row><cell>MFP(0.05, 0.05)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 7 .</head><label>7</label><figDesc><div><p><s>Summary of 'major' models and corresponding measures of separation.</s></p></div></figDesc><table><row><cell>Prognostic factors</cell></row></table><note><p><s>Tumor size, No. of pos.</s><s>lymph nodes (transformed), Tumor grade (2/3 vs. 1), Hormone receptor status 1.308 0.290 0.714 doi:10.1371/journal.pone.0149977.t007</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">PLOS ONE | DOI:10.1371/journal.pone.0149977March 3, 2016  </note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>We thank Tim Haeussler and Clemens Wachter for their assistance in preparing the manuscript.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" />			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Prognosis research strategy (PROGRESS) 1: A framework for researching clinical outcomes</title>
		<author>
			<persName><forename type="first">H</forename><surname>Hemingway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Croft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Perel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Hayden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Abrams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Timmis</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.e5595</idno>
		<idno type="PMID">23386360</idno>
	</analytic>
	<monogr>
		<title level="j">Brit Med J</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="page">e5595</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Prognosis research strategy (PROGRESS) 2: Prognostic factor research</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Riley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Hayden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Steyerberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kgm</forename><surname>Moons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Abrams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Kyzas</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pmed.1001380</idno>
		<idno type="PMID">23393429</idno>
	</analytic>
	<monogr>
		<title level="j">PLOS Med</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">e1001380</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Prognosis research strategy (PROGRESS) 3: Prognostic model research</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Steyerberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kgm</forename><surname>Moons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Van Der Windt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Hayden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Perel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schroter</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pmed.1001381</idno>
		<idno type="PMID">23393430</idno>
	</analytic>
	<monogr>
		<title level="j">PLOS Med</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">e1001381</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Prognosis research strategy (PROGRESS) 4: Stratified medicine research</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Hingorani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Windt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Riley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Abrams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kgm</forename><surname>Moons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Steyerberg</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.e5793</idno>
		<idno type="PMID">23386361</idno>
	</analytic>
	<monogr>
		<title level="j">Brit Med J</title>
		<imprint>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models</title>
		<author>
			<persName><forename type="first">F</forename><surname>Parisi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>González</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nadler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Camp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Rimm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kluger</surname></persName>
		</author>
		<idno type="DOI">10.1186/bcr2633</idno>
		<idno type="PMID">20809974</idno>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">R66</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Azim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Michiels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zagouri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Delaloge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Filipits</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Namer</surname></persName>
		</author>
		<idno type="DOI">10.1093/annonc/mds645</idno>
		<idno type="PMID">23337633</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="647" to="654" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the transbig multicenter independent validation series</title>
		<author>
			<persName><forename type="first">C</forename><surname>Desmedt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Piette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Loi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lallemand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Haibe-Kains</surname></persName>
		</author>
		<idno type="PMID">17545524</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="3207" to="3214" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer</title>
		<author>
			<persName><forename type="first">P</forename><surname>Dubsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Filipits</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jakesz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rudas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Singer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Greil</surname></persName>
		</author>
		<idno type="DOI">10.1093/annonc/mds334</idno>
		<idno type="PMID">23035151</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="640" to="647" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>et al on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Hatzis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pusztai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Valero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Booser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Esserman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lluch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Med Assoc</title>
		<imprint>
			<biblScope unit="volume">305</biblScope>
			<biblScope unit="page" from="1873" to="1881" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Development and validation of a novel platform-independent metastasis signature in human breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shilkrut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Speers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wilder-Romans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Lawrence</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0126631</idno>
		<idno type="PMID">25974184</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">e0126631</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">T</forename><surname>Herold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Jurinovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Metzeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Boulesteix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bergmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Seiler</surname></persName>
		</author>
		<idno type="DOI">10.1038/leu.2011.125</idno>
		<idno type="PMID">21625232</idno>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1639" to="1645" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Identification of clinically useful cancer prognostic factors: What are we missing? (Editorial)</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Mcshane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<idno type="PMID">16030294</idno>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="1023" to="1025" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Expectations, validity, and reality in omics</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Ioannidis</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jclinepi.2010.04.002</idno>
		<idno type="PMID">20573481</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="945" to="949" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems</title>
		<author>
			<persName><forename type="first">K</forename><surname>Hess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Qi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Iwamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Symmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pusztai</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2105-12-463</idno>
		<idno type="PMID">22132775</idno>
	</analytic>
	<monogr>
		<title level="j">BMC Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">463</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Mcshane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Cavenagh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">G</forename><surname>Lively</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Eberhard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Bigbee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Williams</surname></persName>
		</author>
		<idno type="DOI">10.1186/1741-7015-11-220</idno>
		<idno type="PMID">24228635</idno>
	</analytic>
	<monogr>
		<title level="j">BMC medicine</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">220</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Nevins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dressman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pittman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>West</surname></persName>
		</author>
		<idno type="PMID">12928487</idno>
	</analytic>
	<monogr>
		<title level="j">Hum Mol Genet</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="R153" to="R157" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Stepwise classification of cancer samples using clinical and molecular data</title>
		<author>
			<persName><forename type="first">A</forename><surname>Obulkasim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Meijer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van De Wiel</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2105-12-422</idno>
		<idno type="PMID">22034839</idno>
	</analytic>
	<monogr>
		<title level="j">BMC Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">422</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Integration of clinical and gene expression data has a synergetic effect on predicting breast cancer outcome</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Van Vliet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Horlings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Van De Vijver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mjt</forename><surname>Reinders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lfa</forename><surname>Wessels</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0040358</idno>
		<idno type="PMID">22808140</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">2012</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">e40358</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">A generic cycling hypoxia-derived prognostic gene signature: application to breast cancer profiling</title>
		<author>
			<persName><forename type="first">R</forename><surname>Boidot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Branders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Helleputte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">I</forename><surname>Rubio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dupont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Feron</surname></persName>
		</author>
		<idno type="PMID">25216520</idno>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="6947" to="6963" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Study of integrated heterogeneous data reveals prognostic power of gene expression for breast cancer survival</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Neapolitan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Jiang</surname></persName>
		</author>
		<idno>2015: 10</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">e0117658</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Added predictive value of high-throughput molecular data to clinical data and its validation</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Boulesteix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<idno type="DOI">10.1093/bib/bbq085</idno>
		<idno type="PMID">21245078</idno>
	</analytic>
	<monogr>
		<title level="j">Brief Bioinform</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="215" to="229" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Inventory of prostate cancer predictive tools</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Shariat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">I</forename><surname>Karakiewicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Margulis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Kattan</surname></persName>
		</author>
		<idno type="DOI">10.1097/MOU.0b013e3282f9b3e5</idno>
		<idno type="PMID">18382238</idno>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Urol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="279" to="296" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">A systematic review finds prediction models for chronic kidney disease were poorly reported and often developed using inappropriate methods</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Collins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Omar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shanyinde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Yu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jclinepi.2012.06.020</idno>
		<idno type="PMID">23116690</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="268" to="277" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Breast Cancer Study Group. Validation of existing and development of new prognostic classification schemes in node negative breast cancer</title>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hübner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schmoor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schumacher</surname></persName>
		</author>
		<author>
			<persName><surname>For The German</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res Tr</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="149" to="163" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title/>
		<author>
			<persName><surname>Corrigendum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res Tr</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="191" to="192" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Prognostic models: A methodological framework and review of models for breast cancer</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<idno type="DOI">10.1080/07357900802572110</idno>
		<idno type="PMID">19291527</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Invest</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="235" to="243" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">A prognostic index in primary breast cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Haybittle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Blamey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Elston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Doyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Campbell</surname></persName>
		</author>
		<idno type="PMID">7073932</idno>
	</analytic>
	<monogr>
		<title level="j">Brit J Cancer</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="361" to="366" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Blamey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">O</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Pinder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ahs</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Macmillan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dal</forename><surname>Morgan</surname></persName>
		</author>
		<idno type="PMID">17321736</idno>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="1548" to="1555" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Treatment of primary breast cancer at the surgical unit of the Charité 1984-1998</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Winzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Buchholz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Guski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Frohberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Diekmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Possinger</surname></persName>
		</author>
		<idno type="DOI">10.1159/000356805</idno>
		<idno type="PMID">24356564</idno>
	</analytic>
	<monogr>
		<title level="j">Onkologie</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="727" to="736" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Regression models and life tables (with discussion)</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Cox</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J R Stat Soc C-App</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="187" to="200" />
			<date type="published" when="1972">1972</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title level="m" type="main">Modeling survival in colon cancer: a methodological review. Mol Cancer</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Holbert</surname></persName>
		</author>
		<idno type="PMID">17295918</idno>
		<imprint>
			<date type="published" when="2007">2007</date>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">15</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Time-dependence of hazard ratios for prognostic factors in primary breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Hilsenbeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Ravdin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>De Moor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Chamness</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Osborne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Clark</surname></persName>
		</author>
		<idno type="PMID">10066085</idno>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res Treat</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="227" to="237" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Breast cancer prognostic classification in the molecular era: the role of histological grade</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Rakha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Reis-Filho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Baehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Dabbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Decker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Eusebi</surname></persName>
		</author>
		<idno type="DOI">10.1186/bcr2607</idno>
		<idno type="PMID">20804570</idno>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">207</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Done</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Mccready</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Boerner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kulkarni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Leong</surname></persName>
		</author>
		<idno type="DOI">10.1186/bcr3017</idno>
		<idno type="PMID">21939527</idno>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">R92</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Review of survival analyses published in cancer journals</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Stavola</surname></persName>
		</author>
		<author>
			<persName><surname>De</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Love</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Stepniewska</surname></persName>
		</author>
		<idno type="PMID">7640241</idno>
	</analytic>
	<monogr>
		<title level="j">Brit J Cancer</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="511" to="518" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Reporting of prognostic studies of tumor markers: a review of published articels in relation to REMARK guidelines</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mallett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Timmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.bjc.6605462</idno>
		<idno type="PMID">19997101</idno>
	</analytic>
	<monogr>
		<title level="j">Brit J Cancer</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="173" to="180" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Collins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Reitsma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Moons</surname></persName>
		</author>
		<idno type="DOI">10.7326/M14-0697</idno>
		<idno type="PMID">25560714</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="55" to="63" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title level="m" type="main">Response: Reporting recommendations for tumor marker prognostic studies (REMARK)</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Mcshane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Taube</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Clark</surname></persName>
		</author>
		<idno type="PMID">16368950</idno>
		<imprint>
			<date type="published" when="2005">2005</date>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="1855" to="1856" />
		</imprint>
	</monogr>
	<note>Journal of the National Cancer Institute</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mcshane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Taube</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pmed.1001216</idno>
		<idno type="PMID">22675273</idno>
	</analytic>
	<monogr>
		<title level="j">PLOS Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">E1001216</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Multiple imputation of missing values</title>
		<author>
			<persName><forename type="first">P</forename><surname>Royston</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stata J</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="227" to="241" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title level="m" type="main">Modeling survival data: extending the Cox model. 1 st ed</title>
		<author>
			<persName><forename type="first">T</forename><surname>Therneau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Grambsch</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2000">2000</date>
			<publisher>Springer-Verlag</publisher>
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">A new proposal for multivariable modelling of time-varying effects in survival data based on fractional polynomial time-transformation</title>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Royston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Look</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrical J</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="453" to="473" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Comparison of procedures to assess non-linear and time-varying effects in multivariable models for survival data</title>
		<author>
			<persName><forename type="first">A</forename><surname>Buchholz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrical J</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="308" to="331" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<monogr>
		<title level="m" type="main">Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables</title>
		<author>
			<persName><forename type="first">P</forename><surname>Royston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Regression using fractional polynomials of continuous covariates-parsimonious parametric modeling</title>
		<author>
			<persName><forename type="first">P</forename><surname>Royston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J R Stat Soc C-App</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="429" to="267" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Modelling the effects of standard prognostic factors in node positive breast cancer</title>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Royston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bojar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schmoor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schumacher</surname></persName>
		</author>
		<author>
			<persName><surname>The German</surname></persName>
		</author>
		<idno type="PMID">10206288</idno>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Study Group (GBSG)</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="1752" to="1760" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>Brit J Cancer</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Selection of important variables and determination of functional form for continuous predictors in multivariable model building</title>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Royston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Binder</surname></persName>
		</author>
		<idno type="PMID">18058845</idno>
	</analytic>
	<monogr>
		<title level="j">Stat Med</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="5512" to="5528" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">A new measure of prognostic separation in survival data</title>
		<author>
			<persName><forename type="first">P</forename><surname>Royston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<idno type="PMID">14981672</idno>
	</analytic>
	<monogr>
		<title level="j">Stat Med</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="723" to="748" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">A simulation study of predictive ability measures in a survival model I: explained variation measures</title>
		<author>
			<persName><forename type="first">B</forename><surname>Choodari-Oskooei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Royston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mkb</forename><surname>Parmar</surname></persName>
		</author>
		<idno type="DOI">10.1002/sim.4242</idno>
		<idno type="PMID">21520455</idno>
	</analytic>
	<monogr>
		<title level="j">Stat Med</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page">2627</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Estimating a time-dependent concordance index for survival predictor models with covariate dependent censoring</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Gerds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Kattan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schumacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stat Med</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="2173" to="2184" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<monogr>
		<author>
			<persName><surname>Statacorp</surname></persName>
		</author>
		<title level="m">Stata: Release 13. Statistical Software. College Station, TX: StataCorp LP</title>
				<imprint>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Explained variation for survival models</title>
		<author>
			<persName><forename type="first">P</forename><surname>Royston</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stata J</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="83" to="96" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Barton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zabaglo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>'hern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ferguson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Neill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<idno type="DOI">10.1038/bjc.2012.166</idno>
		<idno type="PMID">22531639</idno>
	</analytic>
	<monogr>
		<title level="j">Brit J Cancer</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="1760" to="1765" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Nottingham PrognosticIndex Plus (NPI+): a modern clinical decision making tool in breast cancer</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Rakha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Soria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lemetre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Powe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Nolan</surname></persName>
		</author>
		<idno type="DOI">10.1038/bjc.2014.120</idno>
		<idno type="PMID">24619074</idno>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="1688" to="1697" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">on behalf of the STRATOS initiative. STRengthening Analytical Thinking for Observational Studies: the STRATOS initiative</title>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Abrahamowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Le Cessie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Carpenter</surname></persName>
		</author>
		<idno type="DOI">10.1002/sim.6265</idno>
		<idno type="PMID">25074480</idno>
	</analytic>
	<monogr>
		<title level="j">Stat Med</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="5413" to="5432" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
